Blog - Page 4081 of 5386

MondayNov 03, 2008 4:07 am

Maxygen, Inc. (NASDAQ: MAXY)

Maxygen, Inc. (NASDAQ: MAXY) was founded with the purpose of developing important commercial products by leveraging biotechnology. Since then, the company has established a pipeline of product candidates that address unmet medical needs. Maxygen’s key protein pharmaceutical programs include: MAXY-G34 , an improved G-CSF protein to treat neutropenia; MAXY-VII , an improved factor VIIa protein to treat hemophilia; and MAXY-4 , an improved CTLA4-Ig protein to treat rheumatoid arthritis. For further information, visit the Company's web site at www.maxygen.com.

MondayNov 03, 2008 4:07 am

Marifil Mines Ltd. (TSX: MNKD)

Marifil Mines Ltd. (TSX: MFM CN), a Canadian resource exploration company is focused on aggressively exploring for precious and base metals in Argentina, home of some of the world's most prolific recent discoveries. The Company has built a remarkable portfolio of approximately 20 properties, including several showing bonanza grade gold and silver values. Marifil strategically enhances its properties through focused exploration and drilling, and then utilizes joint ventures with other mining companies to build greater shareholder value. For further information, visit the Company's web site at www.marifilmines.com.

MondayNov 03, 2008 4:06 am

Alyst Acquisition Corporation (AMEX: AYA

Alyst Acquisition Corporation (AMEX: AYA) was incorporated in August of 2006 for the purpose of raising capital from the public equity markets and using the capital to effectuate a merger, capital stock exchange, asset acquisition or other similar business combination. Since the young company’s IPO in June of 2007, Alyst has raised over $64 million and have recently announced a plan of merger with China Networks Media, Ltd. For further information, visit the company website at: www.alyst.net.

MondayNov 03, 2008 4:06 am

MannKind Corporation (NASDAQ: MNKD)

MannKind Corporation (NASDAQ: MNKD), a biopharmaceutical company, has focused their efforts on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Technosphere® Insulin System, the company’s lead investigational product candidate, is currently in Phase 3 clinical trials in the U.S., Europe and Latin America. MannKind believes the Technosphere® Insulin System has the potential to revolutionize the way diabetes is treated. For further information, visit the Company's web site at www.mannkindcorp.com.

MondayNov 03, 2008 4:06 am

Lucas Energy, Inc. (AMEX: LEI)

Lucas Energy, Inc. (AMEX: LEI), an independent oil and gas company, has focused its efforts on building a diversified portfolio of valuable oil and gas assets in the United States. The company is focused on identifying underperforming oil and gas assets, which are then brought online through a careful process of evaluation, application of modern well technology, and stringent management controls. Lucas Energy's financial structure allows it to minimize the high overhead of traditional E&P companies. For further information, visit the Company's web site at www.lucasenergy.com.

MondayNov 03, 2008 4:06 am

Alseres Pharmaceuticals, Inc. (NASDAQ: ALSE)

Alseres Pharmaceuticals, Inc. (NASDAQ: ALSE) is focused on developing therapeutic and diagnostic products designed mainly for disorders in the central nervous system. The company’s robust molecular imaging development program targets the diagnosis of Parkinson's disease and potentially dementia. Altropane, the company's lead molecular imaging product candidate, is currently in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes, including Parkinson's Disease. For further information, visit the Company's web site at www.alseres.com.

MondayNov 03, 2008 4:05 am

Lotus Pharmaceuticals Inc. (OTC BB: LTUS)

Lotus Pharmaceuticals Inc. (OTC BB: LTUS) is becoming one of China’s leaders in the marketing of prescription and over the counter medications. Lotus develops high quality, low cost generic medication and other over the counter brands. Led by their CEO Dr. Liu Zhongyi, the company expects to have continued growth of 20% per year and yearly revenues of over $140 million. For further information, visit the company website at: www.lotuseast.com.

MondayNov 03, 2008 4:05 am

Alphatec Spine, Inc. (NASDAQ: ATEC)

Alphatec Spine, Inc. (NASDAQ: ATEC), a wholly owned subsidiary of Alphatec Holdings, Inc. (Nasdaq:ATEC), is focused on designing, developing, manufacturing and marketing products for the surgical treatment of spine disorders. The company aims to combine world-class customer service with innovative, surgeon-driven design to help improve the aging patient's quality of life. By using innovative solutions, Alphatec well positioned to accomplish its goal. For further information, visit the Company's web site at www.alphatecspine.com.

MondayNov 03, 2008 4:04 am

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), a biopharmaceutical company, is focused on developing novel therapeutics based on RNA interference, or RNAi. By applying its therapeutic expertise in RNAi, the company intends to address substantial medical needs, many of which cannot be effectively addressed with small molecules or antibodies, the current major classes of drugs. Alnylam has taken a leadership role in the translation of RNAi as a new class of innovative medicines with peer-reviewed research efforts published in the world’s top scientific journals including Nature, Nature Medicine, and Cell. For further information, visit the Company's web site at www.alnylam.com.

MondayNov 03, 2008 4:04 am

Lorus Therapeutics, Inc. (AMEX: LRP)

Lorus Therapeutics, Inc. (AMEX: LRP), a biopharmaceutical company, is focused on discovering, researching and developing effective anticancer therapies with high safety profiles. By utilizing its own discovery efforts, in addition to acquisition and in-licensing programs, the company is building a portfolio of anticancer drugs ranging from discovery and preclinical to an advanced Phase II clinical trial. Each of the drug candidates in their current pipeline are backed by a strong intellectual property portfolio. For further information, visit the Company's web site at www.lorusthera.com.

Site Search

Company Search

Maxygen, Inc. (NASDAQ: MAXY)

Marifil Mines Ltd. (TSX: MNKD)

Alyst Acquisition Corporation (AMEX: AYA

MannKind Corporation (NASDAQ: MNKD)

Lucas Energy, Inc. (AMEX: LEI)

Alseres Pharmaceuticals, Inc. (NASDAQ: ALSE)

Lotus Pharmaceuticals Inc. (OTC BB: LTUS)

Alphatec Spine, Inc. (NASDAQ: ATEC)

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)

Lorus Therapeutics, Inc. (AMEX: LRP)

Market Basics

Newsletter Publishers

Public Companies